Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N
NGNE.OQ - Neurogene Inc
Neurogene Inc at TD Cowen Healthcare Conference
Mar 04, 2026 / 03:30PM GMT
=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Thank you everyone for joining us for the Neurogene Fireside chat here at the forty-sixth annual TD Cowan Healthcare Conference. I'm covering analyst Ritu Bal, and joining me today, we have founder and CEO Rachel McMinn. Rachel, thanks for joining us today.
So Neurogene is developing 401, gene therapy for RET syndrome, based on your exact regulated expression gene regulated expression gene therapy platform. For those unfamiliar, could you briefly walk us through the exact platform and how 401 is differentiated?
--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Sure. Well, I

